Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04375956
Title Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients (MITO 27)
Acronym MITO 27
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Age Groups: adult | senior
Covered Countries ITA

No variant requirements are available.